Flutamide
- Generic Name
- Flutamide
- Brand Names
- Eulexin
- Drug Type
- Small Molecule
- Chemical Formula
- C11H11F3N2O3
- CAS Number
- 13311-84-7
- Unique Ingredient Identifier
- 76W6J0943E
- Background
An antiandrogen with about the same potency as cyproterone in rodent and canine species.
- Indication
For the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate
- Associated Conditions
- Stage B2-C metastatic Carcinoma of the Prostate, Stage D2 metastatic Carcinoma of the Prostate
- Associated Therapies
- -
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 1579
- Registration Number
- NCT00005044
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Veterans Affairs Medical Center - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Mercy Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
Phase 2
Withdrawn
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- Burzynski Research Institute
- Registration Number
- NCT00003517
- Locations
- 🇺🇸
Burzynski Clinic, Houston, Texas, United States
Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2024-05-10
- Target Recruit Count
- 62
- Registration Number
- NCT00001521
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath